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Maria Stefania Leto-Barone, MD,a Alberto D’Alcamo, MD,a Gaetana Di Fede, MD,c Giovam Battista Rini, MD,a
and Anne Marie Ditto, MDd Palermo and Verona, Italy, and Chicago, IllBackground: To date, no predictive tests for the clinical response
to allergen-specific immunotherapy (ASI) are available.
Therefore an in vivo or in vitro test would be of great value.
Objective: We sought to evaluate pretreatment parameters used
in diagnosing allergic rhinitis and determining serum specific
IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood
eosinophil counts and to identify whether can be used to predict
clinical improvement in monosensitized patients with allergic
rhinitis with or without asthma treated with immunotherapy.
Methods: Weanalyzed 279 patientswhohadundergone 4 years of
ASI administered either by means of the subcutaneous
immunotherapy (76 patients) or sublingual immunotherapy (203
patients) routes. Serum t-IgE and s-IgE levels, blood eosinophil
counts, and serum s-IgE/t-IgE ratios were calculated and tested
for correlation with clinical response to ASI. Receiver operating
characteristic curves were determined. Predicted probabilities
and predictive areas under the curve were calculated.
Results: The clinical response to ASI was effective in 145
(52.0%) of 279 total patients, 42 (55.2%) of 76 patients treated
with subcutaneous immunotherapy, and 103 (50.7%) of 203
patients treated with sublingual immunotherapy. A significant
correlation was found between the serum s-IgE/t-IgE ratio and
the clinical response to ASI, with high ratios (>16.2) associated
with an effective response. The sensitivity and specificity of the
area under the curve of the ratio were higher than those of
serum s-IgE and t-IgE alone.
Conclusion: The calculation of the serum s-IgE/t-IgE ratio for
predicting the clinical response to ASI offers an advantage
over measuring t-IgE and s-IgE levels in monosensitized
patients for the following allergens: grass, Parietaria judaica,
From aDipartimento di Medicina Clinica e delle Patologie Emergenti and cDipartimento
di Discipline Chirurgiche ed Oncologiche, Universita` degli Studi di Palermo; bDipar-
timento diMedicina Clinica e Sperimentale, Universita` degli Studi di Verona; and dthe
Department of Medicine, Division of Allergy-Immunology, Northwestern University
Feinberg School of Medicine, Chicago.
Supported by grants from the Ministero Italiano dell’Universita` e della Ricerca (MIUR;
fondi ex 60%) to Gabriele Di Lorenzo. Anne Marie Ditto is supported by the Ernest S.
Bazley Grant.
Disclosure of potential conflict of interest: A. M. Ditto is a consultant for Dey
Pharmaceuticals and Abbott Pharmaceuticals and has provided legal consultation/
expert witness testimony in cases related to Stevens-Johnson syndrome and latex
allergy. The rest of the authors have disclosed that they have no conflict of interest.
Received for publication February 19, 2008; revised February 3, 2009; accepted for pub-
lication February 9, 2009.
Available online April 8, 2009.
Reprint requests: Gabriele Di Lorenzo, MD, Dipartimento di Medicina Clinica e delle
Patologie Emergenti, Via del Vespro, 141-90127 Palermo, Italy. E-mail: dilo601@
unipa.it.
0091-6749/$36.00
 2009 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2009.02.012Olea europea, and house dust mite. (J Allergy Clin Immunol
2009;123:1103-10.)
Key words: Allergen-specific immunotherapy, total IgE, specific
IgE, blood eosinophil counts, serum-specific IgE/serum total IgE
ratio, receiver operating characteristic curve
Allergen-specific immunotherapy (ASI) is the practice of
administering gradually increasing doses of allergens (allergen
extracts or vaccines) to reduce allergic symptoms and the need
for medication resulting from exposure to a specific allergen.1,2
Subcutaneous immunotherapy (SCIT) was introduced into
clinical practice early in the 20th century.3 In 1986, sublingual
immunotherapy (SLIT) was introduced.4,5 Double-blind pla-
cebo-controlled trials and meta-analyses confirm the efficacy,
safety, and indications and contraindications of both SCIT and
SLIT.6-8 However, the efficacy of ASI is still debated, despite
solid documentation. ASI, in practice, is indicated for patients
for whom the causative role of the allergen is well documented.
This is determined most commonly in vivo in skin tests (eg, skin
prick testing) and in vitro in quantitative assays for serum specific
IgE (s-IgE; eg, Unicap 100; Phadia, Uppsala, Sweden). It is
unclear how serum total IgE (t-IgE) measurements, alone or in
relation to s-IgE measurements, or blood eosinophil (b-eos)
counts should be interpreted, as well as what role they should
play in selecting patients for ASI in clinical practice. Further-
more, the significance of serum s-IgE levels might vary depend-
ing on the level of t-IgE.
In this study we report the clinical results of 279 patients who
received 4 years of ASI in a clinical setting administered either
by means of SCIT or SLIT. We retrospectively examined the
relationship of the following parameters determined at the time of
diagnosis: diameter of wheal induced by the allergen, serum t-IgE
levels, serum s-IgE levels, b-eos counts, and clinical response to
ASI. We used receiver operating characteristic (ROC) curves to
determine the sensitivity, specificity, and predicted values for
wheal diameter, serum s-IgE level, serum t-IgE level, serum s-IgE/
t-IgE ratio, and b-eos count, all obtained at the time of diagnosis,
in predicting one’s response to ASI.
METHODS
Patients
We retrospectively analyzed monosensitized adult patients consecutively
referred to the Outpatient Allergy Units of the Dipartimento di Medicina
Clinica e delle Patologie Emergenti of the University of Palermo, Italy, and of
the Dipartimento di Medicina Clinica e Medicina Sperimentale of the
University of Verona, Italy, between January 1995 and December 2000 for
evaluation of their allergic rhinitis with or without asthma symptoms. All
patients underwent ASI as part of the therapy for allergic rhinitis. Patients did
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not have other allergic diseases, such as atopic dermatitis, eczema, or nasal
polyps.
A total of 279 subjects (120 male and 159 female subjects), with ages
ranging between 18 and 56 years (mean age, 29.56 8.1 years) were selected:
126 subjects from Palermo and 153 subjects from Verona, respectively.
All patients presented with a clinical diagnosis of allergic rhinitis with or
without asthma based on patient-reported symptoms, physical examination,
and a normal baseline lung function test (baseline FEV1 80% of predictive
value). All patients has positive skin test responses for 1 of 11 common air-
borne allergens, as determined by using the skin prick test method, withmono-
sensitization to 1 of the following: grass, Parietaria judaica, Olea europea, or
house dust mite (HDM). All were treated with ASI for at least 4 years admin-
istered either as SCIT or SLIT. At the time of diagnosis, blood was collected
for analysis of serum t-IgE levels, s-IgE levels, and b-eos counts. Family his-
tory of atopy, as well as history of smoking and onset of respiratory symptoms,
was obtained from each patient. Clinical evaluations were done at baseline and
once a year for the 4-year period of ASI. Evaluations included rhinoscopy and
spirometry (if asthmatic), symptom scoring with the visual analog scale
(VAS), and medication use, referring to the previous year. Evaluations were
conducted at the end of the season for the 3 outdoor allergens and at the end
of February forDermatophagoides pteronyssinus andDermatophagoides far-
inae. More precisely, we performed a clinical evaluation and administered the
VAS for symptoms in June for patients allergic to grass and O europea and in
September for patients allergic to P judaica. For patients allergic to D ptero-
nyssinus and D farinae, we performed a clinical evaluation and administered
the VAS (in February) because the symptoms were worse in autumn, after va-
cations, and during winter (for more information, see the Methods section in
this article’s Online Repository at www.jacionline.org).
Because ASI is commercially available and was prescribed for indications
that are recognized both nationally and internationally, our ethics committees
required written informed consent for the diagnostic tests only, and this was
obtained from each patient.8-10
Immunotherapy intervention
The route of administration of ASI (SCIT or SLIT) was chosen by the
patient to ensure compliance. Each patient received the maximum tolerated
dose, per the manufacturers recommendations, for both SCIT and SLIT. All
the patients in this study tolerated the maximum dose indicated by the
manufacturers recommendations as follows. For SCIT, the maintenance dose
was 0.8mL, which corresponds to 1.6mg of themajor allergen of grass, 0.4mg
of the major allergen of P judaica, 9.6 mg of the major allergen of O europea,
and 3.84 mg of the major allergens of D pteronyssinus and D farinae. On the
other hand, for SLIT, the maintenance dose was 60 drops (1 drop 5 25 mL)
administered 3 times a week on alternate days, which corresponds to 28.2
mg of the major allergen of grass, 6.6 mg of the major allergen of P judaica,
169.2 mg of the major allergen ofO europea, and 67 mg of the major allergens
of D pteronyssinus and D farinae. These doses were administered monthly.
Immunotherapy with grass, P judaica, andO europea pollen was not interrup-
ted during the spring, but the dose was halved (see the Methods section in this
article’s Online Repository).Assessment of symptoms and medication use
The effectiveness of ASI was evaluated on the basis of clinical response
(reduction in nasal and pulmonary symptoms) and reduction of the pharma-
cotherapy taken on an as-needed basis (eg, oral second-generation H1-antihis-
tamine for rhinitis and inhaled short-acting b2-agonist for asthma
symptoms).10,11 Patients were not previously treated with nasal or inhaled
corticosteroids.
VAS. To evaluate symptom response to ASI and reduction of pharma-
cotherapy, we used a VAS sufficiently sensitive to detect changes in symptom
severity (see the Methods section in this article’s Online Repository).12,13
The response to ASI was determined clinically by asking the patient the
following: ‘‘Do you feel better than you did before therapy?’’ The answer
could be one of the following:
1. I have not noticed any improvement since I have used ASI.
2. I noticed a worsening of symptoms since I have used ASI.
3. I noticed that my symptoms improved since I have used ASI.
When we analyzed the 1624 ASI VAS responses throughout the 4-year
study, we noticed that patients who stated improvement of symptoms during
immunotherapy indicated a reduction in their rhinitis (or asthma) VAS values
of at least 30% compared with their baseline VAS values before starting
immunotherapy at the time of diagnosis. To be sure of the results, for each
subject, we used all the ASI values obtained for each year, calculated the
mean, and then subtracted the baseline VAS (VASb) from themean of the VAS
obtained over 4 years. Then we divided the result by the baseline VAS value
and multiplied by 100, as shown by the following formula:
VAS decrease ð%Þ 5 ðMean VAS2VASbÞ
VASb
3 100
We evaluated the ASI as effective if the mean of the VAS scores for the 4
years showed a 30% decreasewith respect to the value of the VAS score before
ASI by using the formula reported above and if the values of the rescue
medications indicated at the third and fourth years of ASI were 0 or 1. In all
other cases, ASI was evaluated as ineffective. Symptom scoring and the
medication used were reviewed by a physician (PM for Palermo and NM for
Verona).
Spirometry. FEV1 and forced expiratory vital capacity were mea-
sured with a Gould 2400 automated system (Sensormedics BV, Bilthoven,
Netherlands) by using the highest of 3 successive measurements, provided
that the difference between measurements was within 100 mL. Spirometric
results were followed each year for 4 years. There was no significant
change in FEV1 or forced expiratory vital capacity (all >80% of predicted
value) in any patient, irrespective of whether the patient responded clini-
cally to ASI.
TABLE I. Characteristics of cohort study patients examined in the
2 centers
No. of patients 279
Age (y)* 29.5 (28.6-30.5)
Male/female sex 120/159
SCIT/SLIT 76/203
Atopic family history (yes/no) 116/163
Passive smoking (yes/no) 123/156
Rhinitis/rhinitis plus asthma 152/127
Onset of symptoms (y)* 7.1 (6.4-7.7)
Pollens/HDM sensitization (no) 106/173
Response to ASI (effective/ineffective) 145/134
SPT to allergen (mm) 5.4 (5.3-5.5)
Serum t-IgE level (kU/L) 139.3 (121.4-159.9)
Serum s-IgE level (kAU/L) 20.2 (17.6-23.0)
b-eos Counts (cells 3 1023 mL) 0.35 (0.34-0.37)
Serum s-IgE/t-IgE* ratio 14.4 (12.3-16.9)
*Mean (95% CI).
Geometric mean after logarithmic transformation (95% CI).
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(Alk-Abello´, Milan, Italy) were performed and evaluated on the volar aspect
of the forearm after withholding antihistamines for at least 5 days. The panel
included the following extracts: pollens (grass [Phleum pratense], mugwort
[Artemisia vulgaris], pellitory of the wall or sticky weed [P judaica], and
trees [O europea and Cupressus species]), HDM (D pteronyssinus and D
farinae), molds (Alternaria alternata and Aspergillus fumigatus), and animal
dander (cat and dog), as well as a negative control (glycerinated saline) and a
positive control (histamine, 10 mg/mL). A positive response was defined as
any wheal with a diameter 3 mm larger than that elicited by the negative con-
trol 15 minutes after application.14 The wheal diameters were reported for
each patient.
TABLE II. Characteristics of the cohort study patients in respect to effective or ineffective clinical response to ASI
All patients
(n 5 279)
Patients treated
with SCIT (n 5 76)
Patients treated
with SLIT (n 5 203)
Effective
clinical
response
Ineffective
clinical
response
P
value
Effective
clinical
response
Ineffective
clinical
response
P
value
Effective
clinical
response
Ineffective
clinical
response
P
value
Patients, no. (%) 145 (52.0) 134 (48.0) 42 (55.2) 34 (44.8) 103 (50.7) 100 (49.3)
Age (y)* 30.3
(28.9-31.7)
28.7
(27.4-30.1)
.1 29.8
(26.9-32.7)
29.6
(26.7-32.5)
.9 30.5
(28.9-32.0)
28.5
(26.9-30.0)
.06
Male/Female sex 52/93 68/66 .01 11/31 19/15 .01 41/62 49/51 .2
Male (%) 35.8 50.7 26.2 55.9 39.8 49.0
Female (%) 64.1 49.2 73.8 44.1 60.2 51.0
SCIT/SLIT 42/103 34/100 .5 NA NA NA NA NA NA
SCIT group (%) 28.9 25.3
SLIT group (%) 70.1 74.7
Atopic family
history (yes/no)
64/81 52/82 .4 36/6 22/12 .06 28/75 30/70 .7
Positive family
history (%) group
44.1 38.8 85.7 64.7 27.2 30.0
Negative family
history group (%)
55.9 61.2 14.3 35.3 72.8 70.0
Passive smoking
(yes/no)
65/80 58/76 .8 16/26 14/20 .9 49/54 44/56 .7
Positive smoking
group (%)
44.8 43.3 38.1 41.2 47.6 44.0
Negative smoking
group (%)
55.2 56.7 61.9 58.8 52.4 56.0
Rhinitis/rhinitis plus
asthma
72/73 80/54 .1 22/20 20/14 .7 50/53 60/40 .1
Rhinitis group (%) 49.7 59.7 52.4 58.8 48.5 60.0
Rhinitis-asthma
group (%)
50.3 40.3 47.6 41.2 51.5 40.0
Onset of symptoms (y)* 6.6 (5.8-7.5) 7.5 (6.5-8.4) .2 7.1 (5.4-8.7) 8.9 (6.6-11.2) .1 6.5 (5.5-7.5) 7.0 (5.9-8.0) .4
Pollens/HDM
sensitization
97/48 76/58 .1 24/18 15/19 .3 73/30 61/39 .1
Pollens group (%) 66.9 56.7 57.1 44.1 70.9 61.0
Grass, no. (%) 4 (2.7) 12 (8.9) 1 (2.4) 2 (5.9) 3 (2.9) 10 (10.0)
P judaica, no. (%) 90 (62.1) 45 (33.6) 23 (54.7) 11 (32.3) 67 (65.1) 34 (34.0)
O europea, no. (%) 3 (2.1) 19 (14.2) 0 (0) 2 (5.9) 3 (2.9) 17 (17.0)
HDM, no. (%) 48 (33.1) 58 (43.3) 18 (42.9) 19 (55.9) 30 (29.1) 39 (39.0)
SPT response
to allergen (mm)
5.4 (5.2-5.6) 5.4 (5.2-5.7) .9 5.4 (5.1-5.8) 5.3 (4.9-5.7) .9 5.5 (5.3-5.7) 5.4 (5.2-5.6) .9
Serum t-IgE level
(kU/L)
84.2
(72.7-97.7)
240.2
(196.2-294.2)
<.0001 105.2
(80.8-137.1)
266.7
(177.4-401.0)
.0007 76.9
(64.3-91.9)
231.8
(182.9-293.9)
<.0001
Serum s-IgE level
(kAU/L)
30.5 (26.1-35.7) 12.9 (10.6-15.6) <.0001 38.5 (28.6-51.9) 19.3 (12.7-29.2) .01 27.7 (23.1-33.3) 11.2 (9.1-13.9) <.0001
b-eos Counts
(cells 3 1023 mL)
0.31 (0.29-0.32) 0.46 (0.42-0.49) <.0001 0.30 (0.27-0.34) 0.46 (0.39-0.53) .0006 0.31 (0.29-0.34) 0.45 (0.42-0.49) <.0001
Serum s-IgE/t-IgE* ratio 36.2 (33.3-39.5) 5.4 (4.4-6.6) <.0001 36.6 (29.6-45.2) 7.2 (5.6-9.4) <.0001 36.1 (33.1-39.3) 4.8 (3.7-6.2) <.0001
Patient no. (%) with
s-IgE/t-IgE ratio
>16.2%
141 (97.2) 17 (12.7) <.0001 41 (97.6) 2 (5.9) <.0001 100 (97.1) 15 (15.0) <.0001
Patient no. (%) with
s-IgE/t-IgE ratio
16.2%
4 (2.8) 117 (87.3) 1 (2.4) 32 (94.1) 3 (2.9) 85 (85.6)
NA, Not applicable.
*Mean (95% CI).
Geometric mean after logarithmic transformation (95% CI).
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Patients with
rhinitis (n 5 152)
Patients with
rhinitis plus asthma (n 5 127)
Effective clinical
response
Ineffective clinical
response P value
Effective clinical
response
Ineffective clinical
response P value
Patients, no. (%) 72 (47.4) 80 (52.6) 73 (57.5) 54 (42.5)
Age (y)* 29.3 (27.5-31.2) 28.3 (26.6-30.0) .4 31.3 (29.2-33.3) 29.4 (27.2-31.6) .2
Male/female sex 25/47 41/39 .04 27/46 27/27 .1
Male (%) 34.7 51.2 37.0 50.0
Female (%) 65.3 48.8 63.0 50.0
SCIT/SLIT 22/50 20/60 .4 20/53 14/40 .9
SCIT group (%) 30.6 25.0 27.4 26.0
SLIT group (%) 69.4 75.0 72.6 74.0
Atopic family history (yes/no) 36/36 34/46 .4 28/45 18/36 .5
Positive family history group (%) 50.0 42.5 38.4 33.3
Negative family history group (%) 40.0 57.5 61.6 66.7
Passive smoking (yes/no) 30/42 33/47 .9 35/38 25/29 .8
Positive smoking group (%) 41.7 41.2 48.0 46.3
Negative smoking group (%) 58.3 58.8 52.0 53.7
Onset of symptoms (y) 5.1 (4.2-6.0) 7.2 (5.9-8.5) .01 8.1 (6.8-9.5) 7.9 (6.4-9.4) .5
Pollens/HDM sensitization 45/27 46/34 .6 52/21 30/24 .1
Pollens group (%) 62.5 57.5 71.2 55.6
HDM group (%) 37.5 42.5 28.8 44.4
Grass, no. (%) 1 (1.4) 8 (10) 3 (4.1) 4 (7.4)
P judaica, no. (%) 43 (59.7) 24 (30) 47 (64.4) 21 (38.9)
O europea, no. (%) 1 (1.4) 14 (17) 2 (2.7) 5 (9.3)
HDM, no. (%) 27 (37.5) 34 (43) 21 (28.8) 24 (44.4)
SPT response to allergen (mm) 5.3 (5.0-5.6) 5.3 (5.1-5.6) .7 5.4 (5.1-5.6) 5.3 (5.0-5.6) .8
Serum t-IgE level (kU/L) 84.2 (68.7-103.2) 206.4 (161.5-263.8) <.0001 84.2 (67.6-104.9) 300.8 (212.3-428.2) <.0001
Serum s-IgE level (kAU/L) 30.1 (24.6-37.5) 10.0 (7.9-12.7) <.0001 30.9 (24.6-38.7) 18.6 (13.6-25.3) .01
b-eos Counts (cells 3 1023 mL) 0.31 (0.29-0.33) 0.40 (0.37-0.42) <.0001 0.30 (0.28-0.33) 0.43 (0.40-0.47) <.0001
Serum s-IgE/t-IgE* ratio 41.5 (36.9-48.1) 9.9 (7.6-12.2) <.0001 39.8 (35.1-44.5) 8.1 (8.5-9.7) <.0001
Patient no. (%) with s-IgE/t-IgE ratio >16.2% 70 (97.2) 10 (12.5) <.0001 71 (97.3) 7 (13.0) <.0001
Patient no. (%) with s-IgE/t-IgE ratio 16.2% 2 (2.8) 70 (87.5) 2 (2.7) 47 (87.0)
*Mean (95% CI).
Geometric mean after logarithmic transformation (95% CI).Serum t-IgE and s-IgE levels
A blood sample was processed at the time of diagnosis and before ASI.
Serum t-IgE and s-IgE levels were determined by using the Unicap 100
with the fluoroimmunoassay technique (Phadia, Uppsala, Sweden),
according to the manufacturer’s instructions. Results for both serum t-
IgE and s-IgE measurements were expressed in kilounits per liter and
equilibrated against the World Health Organization standard for IgE: 1 kU
for t-IgE and 1 kAU for s-IgE was equal to 2.4 ng/mL, respectively.
Serum t-IgE levels were determined with a detection limit of 2 kU/L and
an upper limit of 5000 kU/L. Serum s-IgE levels were determined with a
detection limit of 0.35 kAU/L and an upper limit of 100 kAU/L. In all
patients the s-IgE level was measured for the same allergens used in the
skin prick tests (11 allergens).15,16 All patients were monosensitized (had
a positive skin prick test response for only 1 allergen and presented with
s-IgE for the same allergen). For the calculation of the ratio, we used the
following formula:
s2IgE=t2IgE ratio 5
s2IgE
t2 IgE
3 100
Peripheral b-eos counts. Absolute peripheral b-eos counts were
determined before ASI with a Technicon-H1 blood cell counter (Bayer,
Leverkusen,Germany),with thenormal rangebeing0.10 to0.40 cells/1023mL.17
Statistical analysis
Statistical analysis was performed with the SYSTAT 10 software package
(Systat Software, Inc, San Jose, Calif). Data were reported as the arithmeticmean and 95% CI for the mean when the distribution of the data was normal.
When normality was rejected, data were examined after logarithmic trans-
formation and presented as the geometric mean and the 95% CI for the
geometric mean. We used the Kolmogorov-Smirnov test to evaluate the
normal distribution. Group comparison tests were performedwith the 2-sided t
test. Categorical variables between groups were compared by using the x2 test.
An effective or ineffective response to ASIwas assessed by examining the area
under the ROC curves (c-statistic). Models with an ROC area of at least 0.80
TABLE IV. Multivariate regression using the response to ASI as
variable-dependent
Independent variables r P value
Age (y) 0.095 NS
Male/female sex 20.150 NS
SCIT/SLIT 0.040 NS
Atopic family history 0.054 NS
Rhinitis/rhinitis plus asthma 0.101 NS
Onset of symptoms (y) 20.075 .007
Pollens/HDM sensitization 0.105 NS
Serum s-IgE/t-IgE ratio 0.723 <.0001
Serum t-IgE level 20.342 NS
Serum s-IgE level 0.316 .007
b-eos Counts 20.429 <.0001
SPT response to allergens (mm) 0.009 NS
NS, not significant.
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specificity, 67.9%), serum s-IgE levels (decision point, 9.5 kAU/L; sensitivity, 91.0%; specificity, 46.3%), b-eos
counts (decision point, 0.43 cells 3 1023 mL; sensitivity, 87.6%; specificity, 57.5%), and serum s-IgE/serum
t-IgE ratios (decision point, 16.2%; sensitivity, 97.2%; specificity, 88.1%) by plotting sensitivity in patients
with an effective response to ASI versus 100-specificity in patients with an ineffective response to ASI.were considered to have good predictive value.18 For all analyses, a P value of
less than .05 was considered statistically significant.
RESULTS
We examined a total of 120 male and 159 female subjects
(mean age, 29.56 8.1 years) meeting the criteria outlined above.
One hundred fifty-two patients were affected by rhinitis alone,
and 127 were affected by rhinitis plus asthma. Sixteen patients
were monosensitized to grass, 135 to P judaica, 22 to O europea,
and 106 to HDM. Two hundred three (72.8%) patients were trea-
ted with SLIT, and 76 (27.2%) were treated with SCIT. Response
to ASI was considered effective in 145 (52.0%) patients: 4 sensi-
tive to grass, 90 sensitive to P judaica, 3 sensitive to O europea,
and 48 sensitive to HDM. ASI was considered clinically ineffec-
tive in 134 (48.0%) patients: 12 sensitive to grass, 45 sensitive to
P judaica, 19 sensitive to O europea, and 58 sensitive to HDM.
Patient characteristics are reported in Table I. Table II com-
pares patients with an effective clinical response toASIwith those
with an ineffective response, both as a group and according to the
type of ASI (SLIT and SCIT). When comparing all the study
patients, those who had an effective response to ASI differed
significantly from those with an ineffective response in the fol-
lowing characteristics: sex (female subjects better than male sub-
jects, P 5 .01), serum t-IgE levels (low levels better than high
levels, P < .0001), serum s-IgE levels (high levels better than
low levels, P < .0001), b-eos counts (low counts better than
high counts, P < .0001), and serum s-IgE/t-IgE ratios (high ratios
better than low ratios, P < .0001). Between patients with effective
and ineffective clinical responses to SCIT, significant differences
were found with regard to the following characteristics: sex
(female subjects better than male subjects, P 5 .01), serum
t-IgE levels (low levels better than high levels, P 5 .007), serum
s-IgE levels (high levels better than low levels, P 5 .01), b-eos
counts (low counts better than high counts, P < .0001), and serum
s-IgE/t-IgE ratios (high ratios better than low ratios, P < .0001).
Significant differences were found between patients with
effective and ineffective clinical responses to SLIT with regard
to serum t-IgE levels (low levels better than high levels, P <
.0001), serum s-IgE levels (high levels better than low levels,
P < .0001), b-eos counts (low counts better than high counts,
P < .0001), and serum s-IgE/t-IgE ratios (high ratios better thanlow ratios, P < .0001). We did not find a relationship among aller-
gen dosing, total dose received, and clinical response because all
the patients within each group received an equal dose.
Table III shows the characteristics of patients with rhinitis only
and those with rhinitis and asthma symptoms. For patients with
rhinitis only, significant differences were found between those
with effective and ineffective clinical responses toASIwith regard
to serum t-IgE levels (low levels better than high levels, P 
.0001), serum s-IgE levels (high levels better than low levels,
P  .0001), b-eos counts (low counts better than high counts,
P < .0001), and serum s-IgE/t-IgE ratios (high ratios better than
low ratios, P < .0001). For patients with rhinitis and asthma
symptoms, significant differences were found between patients
with effective and ineffective clinical responses toASIwith regard
to serum t-IgE levels (low levels better than high levels, P 
.0001), serum s-IgE levels (high levels better than low levels,
P  .01), b-eos counts (low counts better than high counts,
P < .0001), and serum s-IgE/t-IgE ratios (high ratios better than
low ratios, P < .0001).
Serum t-IgE and s-IgE levels correlated with age (both
showing), whereas the s-IgE/t-IgE ratio was not affected by
age. Regression analysis showed that t-IgE levels (r 5 20.13
[95% CI, 20.24 to 20.01], P 5 .02) and s-IgE levels (r 5
20.17 [95% CI, 20.28 to 20.05], P 5 .004) were inversely re-
lated to age in years, whereas s-IgE/t-IgE ratios did not correlate
with age (P5 .3). In addition, using multivariate regression anal-
ysis, we found that response to ASI is independently related only
to onset of symptoms, s-IgE/t-IgE ratios, s-IgE levels, and
b-eos counts, again confirming that response to ASI is not related
to age (Table IV).
Fig 1 shows the sensitivity and specificity obtained by calculat-
ing ROC curves for serum t-IgE levels, serum s-IgE levels, b-eos
counts, and serum s-IgE/t-IgE ratios and the pairwise compari-
sons of the ROC curves. The area under the curvewas 0.74 for se-
rum t-IgE levels (95% CI, 0.69-0.79), 0.71 for serum s-IgE levels
(95% CI, 0.65-0.76), 0.73 for b-eos counts (95% CI, 0.67-0.78),
and 0.97 for serum s-IgE/t-IgE ratios (95%CI, 0.94-0.98). Signif-
icant differences were found between the s-IgE/t-IgE ratio and
t-IgE levels alone (P < .001), s-IgE levels alone (P < .001), and
b-eos counts (P < .001). No other significant differences were
found.
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ratio of greater than 16.2% had the best sensitivity (97.2%) and
specificity (88.1%) to predict effective ASI, regardless of whether
SCIT or SLIT was used. The sensitivity and specificity of the
decision point for a serum s-IgE/t-IgE ratio of greater than 16.2%,
as obtained from the ROC, was examined for each allergen used
for immunotherapy. Results are as follows: sensitivity and spec-
ificity of 100% for grass; 96.7% and 77.8%, respectively, for P ju-
daica; 100% and 89.5%, respectively, for O europea; and 97.9%
and 93.1%, respectively, for HDM. This is shown in Fig 2. Fig 3
shows the means (6 SD) of VAS scores with regard to rhinitis
and asthma symptoms, respectively. Of note, rescue medication
use decreased with improvement in symptoms, as reflected in
the VAS. Likewise, medication use increased with worsened
symptoms per the VAS (Tables E1-E3).
DISCUSSION
Our investigation shows that the serum s-IgE/t-IgE ratio
significantly correlates with the clinical response to ASI admin-
istered through both the SCITand SLIT routes.We considered the
result of ASI to 4 aeroallergens epidemiologically very important
in our geographic area (ie, grass, P judaica, O europea, and
HDM) in a total of 279 patients.14 Tests to predict the outcome
of ASI would be of tremendous help in daily practice, but data
about this aspect of immunotherapy have not been reported.
Therefore we evaluated clinical, functional, and laboratory char-
acteristics evaluated at the time of clinical diagnosis and analyzed
the variables that were statistically different between the patients
with effective and ineffective clinical responses to ASI after 4
years. These were serum t-IgE levels, serum s-IgE levels, b-eos
counts, and serum s-IgE/t-IgE ratios. We compared these varia-
bles, considering the clinical response to ASI, apart from the route
of administration.We found that for all the allergens considered, a
serum s-IgE/t-IgE ratio of greater than 16.2% correlated with an
effective clinical response to ASI with a sensitivity of 97.2% and a
specificity of 88.1%. Our analyses demonstrated that the serum s-
IgE/t-IgE ratio is superior to both serum t-IgE and s-IgE levels
alone in predicting clinical response to ASI. This is based on
only 1 measurement of s-IgE and t-IgE levels, which is a limita-
tion of the study. Both samples were drawn at the time of diagno-
sis when patients were manifesting symptoms and therefore
during a time when the patient was presumed to have a high clin-
ical exposure.Measurements were obtained uniformly for all sub-
jects at the time of diagnosis, generally during peak allergen
exposure, thus reflecting a real-life situation comparable with
the usual clinical practice for the management of such patients.
Certainly, these considerations might be too speculative, and fur-
ther studies with serial evaluations of IgE concentrations, includ-
ing measurements during the season to look for the ablation of the
seasonal increase in allergen s-IgE levels, are needed to confirm
our results. Measuring allergen-specific IgG levels would also
be useful because these are classically used to demonstrate re-
sponse to ASI. It has been reported that the percentage of allergen
s-IgE is approximately 25% of t-IgE.19 Allergic inflammation is
initiated by allergen molecules cross-linking their corresponding
FIG 2. Sensitivity (Sens) and specificity (Spec) calculated for each allergen
used for ASI by using the ratio of serum s-IgE/serum t-IgE of 16.2% as the
decision point. A, grass; B, Parietaria judaica; C, Olea europa; D, house
dust mites (HDM).
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respectively.receptor-bound s-IgE on the mast cell and basophil surface.20,21
Although it is possible to quantify both serum t-IgE and s-IgE
levels, serum t-IgE levels are not measured because they are not
useful in the clinical diagnosis of allergy to common aeroaller-
gens.15 Thus a higher s-IgE/t-IgE ratio might reflect a higher level
of allergen s-IgE on the mast cell and basophil surface, whereas
this probability is lower when the serum s-IgE/t-IgE ratio is low.
For this reason, it might be helpful to measure the serum t-IgE
level and calculate the serum s-IgE/t-IgE ratio. In fact, as shown
by the area under the curve values of the ROC, this ratio is at least
as accurate, if not better, than serum t-IgE and s-IgE levels alone
at predicting clinical response to ASI. Calculating a decision
point for the ratio that represents a 95% predicted probability for
an effective clinical response for all 4 allergensmight improve the
sensitivity and specificity compared with both serum s-IgE and t-
IgE levels alone. The predicted probability, calculated for each
allergen studied, demonstrated that the cutoff level of greater than
16.2% showed both high specificity (between 77.8% forP judaicaand 100% for grass) and high sensitivity (between 96.7% for
P judaica and 100% for grass and O europea).
The subjects in this study are monosensitized to the aeroaller-
gens deemed most important in Italy.14 We cannot completely ex-
clude the possibility of sensitization to allergens not routinely
tested, nor can we apply the findings to monosensitized patients.
However, it is likely that the amount of s-IgE in the serum reflects
the degree of environmental exposure to individual allergens.
Thus it is conceivable that the higher the s-IgE/t-IgE ratio, the
more clinically relevant the allergen is for a particular patient.
Likewise, the more clinically relevant the allergens included in
the ASI, the more successful ASI will be. A possible mechanism
is that ASI generates allergen-specific regulatory T cells, and gen-
erating regulatory T cells specific to the patient’s dominant and
most relevant allergen might help generate sufficient regulatory
T cells in the respiratory mucosa to suppress bystander IgE re-
sponses to other less relevant allergens, resulting in an overall
decrease in mucosal allergic inflammation.19
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However, the treatment is of long duration. Because not all
patients benefit from treatment, it would be useful to be able to
have specific criteria to determine those patients who might best
benefit from this therapy. We found that the serum s-IgE/t-IgE
ratio is the best predictor of clinical response to allergen-specific
immunotherapy. Although the s-IgE/t-IgE ratio has been already
described in the medical literature, to the best of our knowledge,
this is the first study that demonstrates a possible role of s-IgE/t-
IgE ratio as a predictor of clinical response to allergen-specific
immunotherapy. Our results are applicable only to patients
monosensitized to these 4 allergens studied. In addition, the
lack of precise data about pollen counts might be another
limitation. However, there is no reason to think there was an
important difference between years because the local registries
for pollen counts did not reflect this. In addition, patients with no
response to ASI required more rescue medication compared with
those patients who responded, providing indirect evidence of
adequate pollen counts.
Finally, the lack of a placebo is a limitation of this study.
However, the aim of this study was not to perform a clinical trial
that might be addressed in the future but to search for a potential
explanation for why patients who have received ASI could have
very different response rates and thus to search for possible
predictors of such varied responses. Our study has a retrospective
design and, consequently, has the common limitations of such
types of studies. Nonetheless, we believe that these limitations do
not significantly confound the main finding of our study. How-
ever, this needs to be further investigated, preferably through
studies with a double-blind design, which is the gold standard for
determining the efficacy of any therapy.
Clinical implications: The s-IgE/t-IgE ratio significantly corre-
lated with the clinical response to ASI in monosensitized pa-
tients. This suggests that the s-IgE/t-IgE ratio can be used as a
predictor of clinical response to immunotherapy.
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Immunotherapy intervention
Dose administered of SCIT and SLIT. All the patients in this
study tolerated the maximum dose indicated by the manufacturers recommen-
dations as follows. For SCIT, the maintenance dose was 0.8 mL, which
corresponds to 1.6mg of themajor allergen of grass, 0.4mg of themajor allergen
ofP judaica, 9.6mg of themajor allergen ofOeuropea, and 3.84mg of themajor
allergens ofDpteronyssinus andD farinae. For SLIT, themaintenance dosewas
60 drops (1 drop5 25mL) administered 3 times aweek on alternate days, which
corresponds to 28.2 mg of the major allergen of grass, 6.6 mg of the major aller-
gen ofP judaica, 169.2mgof themajor allergen ofOeuropea, and 67.7mg of the
major allergens of D pteronyssinus and D farinae. These doses were given
monthly. Immunotherapy with grass, P judaica, and O europea pollen was not
interrupted during the spring, but the dose was halved.
The use of a perennial schedulewith grass,P judaica, andO europea pollen
was well tolerated in our patients, as shown by the absence of side effects
associated with administration during the spring, the peak period of these
pollens, both in Sicily and in Veneto.
We did not find a relationship between allergen dosing, total dose received,
and clinical response because all the patients received an equal dose.
Assessment of symptoms and medication use. For
clinical control, with regard to the 3 outdoor allergens, we performed clinical
control and evaluation of the VAS for symptoms at the end of the season,
specifically in June for patients allergic to grass andO europea and in Septem-
ber for patients allergic to P judaica. For patients allergic to D pteronyssinus
and D farinae, we performed clinical control and evaluation of the VAS for
symptoms at the end of February because they are typically increased in au-
tumn, after vacations, and during winter.
In Sicily, however, there is not a well-defined season for grass and P juda-
ica. Thus the use of medication and, perhaps, symptom scoring might be out-
side the pollen season and therefore might be relevant to the assessment of the
efficacy of immunotherapy.Evaluation of clinical response. The clinical response to ASI
was evaluated with separate VASs for rhinitis and asthma. For rhinitis, the
patients assessed their total nasal symptom scores (sneezing, rhinorrhea, nasal
congestion, and nasal pruritis) yearly for 4 years with the VAS. Subjects were
instructed that 0 indicated ‘‘nasal symptoms not at all bothersome’’ and that
100 indicated ‘‘nasal symptoms extremely bothersome.’’ For asthma, the
patients did the same, marking the VAS for all asthma symptoms yearly for 4
years (shortness of breath, chest tightness, cough, and wheezing). Each VAS
was 100 mm horizontal with 0 and 100 on the left and right ends, respectively.
Subjects were instructed that 0 indicated ‘‘no complaints of respiratory
sensation, such as shortness of breath, chest tightness, and breathlessness’’ and
100 indicated ‘‘the worst complaints of respiratory symptoms imaginable.’’
The distance between 0 and the marks the subjects made on the scale was
measured with a Digimatic caliper (Mitutoyo, Kawasaki, Japan).
Rescue medication included an H1-antagonist for relief of rhinitis symp-
toms (loratadine [Claritin], 10 mg; Schering-Plough, Segrate, Italy) and a
short-acting b2-agonist for relief of asthma symptoms (salbutamol [Ventolin],
100 mg per actuation of a metered-dose inhaler; GlaxoSmithKline, Naples,
Italy). We asked patients to indicate the number of packages of loratadine tab-
lets (20 tablets per package) taken in each year and the number of salbutamol
inhalers used in each year. The scale of rescue medication was between 0 and
3. The subjects were instructed that 0 indicated no rescue medication; 1 indi-
cated a maximum of 1 package of loratadine (20 tablets per year; see Table
E1) and 1 salbutamol inhaler (20 mg/y); 2 indicated a maximum of 3 pack-
ages of loratadine (60 tablets per year) and a maximum of 4 salbutamol in-
halers ( 80mg/y); and 3 indicated 4 or more packages of loratadine and 5 or
more salbutamol inhalers (Table E2).
Comparison between SCIT and SLIT in patients with
effective clinical responses to ASI. The comparison between
SCIT and SLIT in patients with an effective clinical response to ASI is shown
in Table E3. Significant differences were noted only for atopic family history
(P < .0001) and serum s-IgE levels (P 5 .02).
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No. of patients
Ineffective clinical
response (n 5 54)
Effective clinical
response (n 5 73)
Rescue medication Before ASI After ASI Before ASI After ASI
0 (no rescue medication) 0 0 0 68
1 (mild use) 10 13 9 5
2 (moderate use) 22 30 35 0
3 (major use) 22 11 29 0
J ALLERGY CLIN IMMUNOL
VOLUME 123, NUMBER 5
DI LORENZO ET AL 1110.e3TABLE E2. H1-antagonist used as rescue medication for symptoms of rhinitis
No. of patients
Ineffective clinical
response (n 5 80)
Effective clinical
response (n 5 72)
Rescue medication Before ASI After ASI Before ASI After ASI
0 (no rescue medication) 0 0 0 0
1 (mild use) 0 0 0 70
2 (moderate use) 22 30 21 2
3 (major use) 58 50 51 0
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SCIT SLIT P value
Patients, no. (%) 42 103
Age (y)* 29.8 (26.8-32.7) 30.5 (28.9-32.1) .6
Male/female sex 11/31 41/62 .1
Male subjects (%) 26.2 39.8
Female subjects (%) 73.8 60.2
Atopic family history (yes/no) 36/6 28/75 <.0001
Positive family history group (%) 85.7 27.2
Negative family history group (%) 14.3 72.8
Passive smoking (yes/no) 16/26 49/54 .3
Positive smoking group (%) 38.1 47.6
Negative smoking group (%) 61.9 52.4
Rhinitis/rhinitis plus asthma 22/20 50/53 .8
Rhinitis group (%) 52.4 48.5
Rhinitis-asthma group (%) 47.6 51.5
Onset of symptoms (y)* 7.1 (5.4-8.7) 6.5 (5.5-7.5) .5
Pollens/HDM sensitization 24/18 73/30 .6
Pollens group (%) 57.1 70.9
HDM group (%) 42.9 29.1
Grass, no. (%) 1 (2.3) 3 (2.9)
P judaica, no. (%) 23 (54.8) 67 (65.0)
O europea, no. (%) 0 3 (2.9)
HDM, no. (%) 18 (42.9) 30 (29.1)
SPT response to allergen (mm) 5.4 (5.2-5.6) 5.4 (5.2-5.6) .8
Serum t-IgE level (kU/L) 105.2 (80.8-137.1) 76.9 (64.4-91.8) .09
Serum s-IgE level (kAU/L) 38.5 (28.5-51.9) 27.7 (23.1-33.3) .02
b-eos Counts (cells 3 1023 mL) 0.30 (0.27-0.36 0.31 (0.29-0.33) .5
Serum s-IgE/t-IgE* ratio 36.6 (29.6-45.2) 36.1 (33.1-39.3) .4
Patient no. (%) with s-IgE/t-IgE ratio >16.2% 41 (97.6) 100 (97.1) .8
Patient no. (%) with s-IgE/t-IgE ratio 16.2% 1 (2.4) 3 (2.9)
SPT, Skin prick test.
*Mean (95% CI).
Geometric mean after logarithmic transformation (95% CI).
